尿激酶溶栓在急性脑梗塞患者治疗中的价值

Value of Urokinase Thrombolysis in the Treatment of Acute Cerebral Infarction

目的:探讨尿激酶溶栓治疗急性脑梗塞临床疗效。方法:择取2015年1月~2019年1月期间某院收治的60例行急性脑梗塞患者参与研究,通过抽签的方式进行随机分组,包括对照组30例和观察组30例。对照组患者开展常规治疗,观察组基于常规疗法行尿激酶溶栓治疗,比较两组患者临床疗效,治疗前后神经功能缺损评分(NIHSS)以及日常生活活动能力(ADL)评分。结果:观察组临床疗效93.33%,对照组临床疗效73.33%,差异经统计学计算存在意义(P<0.05);治疗前两组患者NIHSS和ADL评分无明显差异(P>0.05),治疗后观察组NIHSS评分相比对照组更低,ADL相比对照组更高,差异经统计学计算存在意义(P<0.05)。结论:急性脑梗塞患者行尿激酶溶栓治疗效果理想,可有效改善患者神经功能和生活能力,因此可用于临床推广。

Objective: To investigate the clinical effect of urokinase thrombolysis in the treatment of acute cerebral infarction. Methods: 60 patients with acute cerebral infarction admitted to a hospital from January 2015 to January 2019 were selected to participate in the study. They were randomly divided into control group(30 cases) and observation group(30 cases) by drawing lots. Patients in the control group received routine treatment, while patients in the observation group received urokinase thrombolytic therapy based on routine therapy. The clinical efficacy, NIHSS and ADL scores before and after treatment were compared between the two groups. Results: The clinical efficacy of the observation group was 93.33%, and that of the control group was 73.33%. The difference was statistically significant(P<0.05). There was no significant difference in NIHSS and ADL scores between the two groups before treatment(P>0.05). After treatment, the NIHSS score of the observation group was lower than that of the control group, and ADL was higher than that of the control group, the difference was statistically significant(P<0.05). Conclusion: Urokinase thrombolysis is an ideal treatment for acute cerebral infarction, which can effectively improve the neurological function and living ability of patients, so it can be used for clinical promotion.